News Hunt under pressure over plans to quit EMA Britain could be in "second rank" of medicines access, warn MPs.
News EU drug regulators concerned about Brexit impact European regulators concerned over impact of EMA move.
Views & Analysis Fast-track appraisals and Managed Access Agreements Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.
Views & Analysis High-value, high-cost drugs: how to pay for them Experts call for urgent development of new drug funding mechanisms.
News AZ claims another win for Imfinzi in frontline liver cancer AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
